BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 1531699)

  • 1. Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs.
    Margolis B; Hu P; Katzav S; Li W; Oliver JM; Ullrich A; Weiss A; Schlessinger J
    Nature; 1992 Mar; 356(6364):71-4. PubMed ID: 1531699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Product of vav proto-oncogene defines a new class of tyrosine protein kinase substrates.
    Bustelo XR; Ledbetter JA; Barbacid M
    Nature; 1992 Mar; 356(6364):68-71. PubMed ID: 1311423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
    Katzav S
    Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor-1 induces rapid tyrosine phosphorylation of the vav proto-oncogene product.
    Uddin S; Yetter A; Katzav S; Hofmann C; White MF; Platanias LC
    Exp Hematol; 1996 Apr; 24(5):622-7. PubMed ID: 8605967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vav binds to several SH2/SH3 containing proteins in activated lymphocytes.
    Ramos-Morales F; Druker BJ; Fischer S
    Oncogene; 1994 Jul; 9(7):1917-23. PubMed ID: 8208538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine phosphorylation and activation of Vav GTP/GDP exchange activity in antigen receptor-triggered B cells.
    Gulbins E; Langlet C; Baier G; Bonnefoy-Berard N; Herbert E; Altman A; Coggeshall KM
    J Immunol; 1994 Mar; 152(5):2123-9. PubMed ID: 8133029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases.
    Ellis C; Moran M; McCormick F; Pawson T
    Nature; 1990 Jan; 343(6256):377-81. PubMed ID: 1689011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product.
    Crespo P; Schuebel KE; Ostrom AA; Gutkind JS; Bustelo XR
    Nature; 1997 Jan; 385(6612):169-72. PubMed ID: 8990121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
    Groysman M; Nagano M; Shaanan B; Katzav S
    Oncogene; 1998 Sep; 17(12):1597-606. PubMed ID: 9794237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav.
    Tarakhovsky A; Turner M; Schaal S; Mee PJ; Duddy LP; Rajewsky K; Tybulewicz VL
    Nature; 1995 Mar; 374(6521):467-70. PubMed ID: 7700358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine phosphorylation of adaptor protein 3BP2 induces T cell receptor-mediated activation of transcription factor.
    Qu X; Kawauchi-Kamata K; Miah SM; Hatani T; Yamamura H; Sada K
    Biochemistry; 2005 Mar; 44(10):3891-8. PubMed ID: 15751964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The proto-oncogene Vav product is constitutively tyrosine-phosphorylated in normal human immature T cells.
    Gouy H; Debré P; Bismuth G
    Eur J Immunol; 1995 Nov; 25(11):3030-4. PubMed ID: 7489739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vav: Captain Hook for signal transduction?
    Katzav S
    Crit Rev Oncog; 1995; 6(2):87-97. PubMed ID: 8792085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine phosphorylation of Vav stimulates IL-6 production in mast cells by a Rac/c-Jun N-terminal kinase-dependent pathway.
    Song JS; Haleem-Smith H; Arudchandran R; Gomez J; Scott PM; Mill JF; Tan TH; Rivera J
    J Immunol; 1999 Jul; 163(2):802-10. PubMed ID: 10395673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophosphorylation mutants of the EGF-receptor signal through auxiliary mechanisms involving SH2 domain proteins.
    Li N; Schlessinger J; Margolis B
    Oncogene; 1994 Dec; 9(12):3457-65. PubMed ID: 7970705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The protein tyrosine kinase ZAP-70 can associate with the SH2 domain of proto-Vav.
    Katzav S; Sutherland M; Packham G; Yi T; Weiss A
    J Biol Chem; 1994 Dec; 269(51):32579-85. PubMed ID: 7798261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proto-oncogene products Vav and c-Cbl are involved in the signal transduction through Grb2/Ash in hematopoietic cells.
    Hanazono Y; Odai H; Sasaki K; Iwamatsu A; Yazaki Y; Hirai H
    Acta Haematol; 1996; 95(3-4):236-42. PubMed ID: 8677749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The SH2 and SH3 domain-containing Nck protein is oncogenic and a common target for phosphorylation by different surface receptors.
    Li W; Hu P; Skolnik EY; Ullrich A; Schlessinger J
    Mol Cell Biol; 1992 Dec; 12(12):5824-33. PubMed ID: 1333047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vav family proteins couple to diverse cell surface receptors.
    Moores SL; Selfors LM; Fredericks J; Breit T; Fujikawa K; Alt FW; Brugge JS; Swat W
    Mol Cell Biol; 2000 Sep; 20(17):6364-73. PubMed ID: 10938113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product.
    Deckert M; Tartare-Deckert S; Couture C; Mustelin T; Altman A
    Immunity; 1996 Dec; 5(6):591-604. PubMed ID: 8986718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.